ENSC
Price
$2.24
Change
+$0.02 (+0.90%)
Updated
Jun 27 closing price
Capitalization
5.31M
YMAB
Price
$4.70
Change
-$0.10 (-2.08%)
Updated
Jun 27 closing price
Capitalization
213.34M
39 days until earnings call
Interact to see
Advertisement

ENSC vs YMAB

Header iconENSC vs YMAB Comparison
Open Charts ENSC vs YMABBanner chart's image
Ensysce Biosciences
Price$2.24
Change+$0.02 (+0.90%)
Volume$34.85K
Capitalization5.31M
Y-mAbs Therapeutics
Price$4.70
Change-$0.10 (-2.08%)
Volume$212.17K
Capitalization213.34M
ENSC vs YMAB Comparison Chart in %
Loading...
ENSC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENSC vs. YMAB commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENSC is a Buy and YMAB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ENSC: $2.24 vs. YMAB: $4.70)
Brand notoriety: ENSC and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENSC: 2% vs. YMAB: 100%
Market capitalization -- ENSC: $5.31M vs. YMAB: $213.34M
ENSC [@Biotechnology] is valued at $5.31M. YMAB’s [@Biotechnology] market capitalization is $213.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENSC’s FA Score shows that 1 FA rating(s) are green whileYMAB’s FA Score has 1 green FA rating(s).

  • ENSC’s FA Score: 1 green, 4 red.
  • YMAB’s FA Score: 1 green, 4 red.
According to our system of comparison, YMAB is a better buy in the long-term than ENSC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENSC’s TA Score shows that 4 TA indicator(s) are bullish while YMAB’s TA Score has 6 bullish TA indicator(s).

  • ENSC’s TA Score: 4 bullish, 4 bearish.
  • YMAB’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, YMAB is a better buy in the short-term than ENSC.

Price Growth

ENSC (@Biotechnology) experienced а +10.89% price change this week, while YMAB (@Biotechnology) price change was +6.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

ENSC is expected to report earnings on May 13, 2025.

YMAB is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
YMAB($213M) has a higher market cap than ENSC($5.31M). YMAB YTD gains are higher at: -39.974 vs. ENSC (-72.482). ENSC has higher annual earnings (EBITDA): -6.77M vs. YMAB (-30.39M). YMAB has more cash in the bank: 60.3M vs. ENSC (3.05M). ENSC has less debt than YMAB: ENSC (257K) vs YMAB (603K). YMAB has higher revenues than ENSC: YMAB (88.7M) vs ENSC (0).
ENSCYMABENSC / YMAB
Capitalization5.31M213M2%
EBITDA-6.77M-30.39M22%
Gain YTD-72.482-39.974181%
P/E Ratio0.02N/A-
Revenue088.7M-
Total Cash3.05M60.3M5%
Total Debt257K603K43%
FUNDAMENTALS RATINGS
ENSC vs YMAB: Fundamental Ratings
ENSC
YMAB
OUTLOOK RATING
1..100
4775
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9996
PRICE GROWTH RATING
1..100
9364
P/E GROWTH RATING
1..100
68100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENSC's Valuation (27) in the null industry is in the same range as YMAB (33) in the Pharmaceuticals Major industry. This means that ENSC’s stock grew similarly to YMAB’s over the last 12 months.

ENSC's Profit vs Risk Rating (100) in the null industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that ENSC’s stock grew similarly to YMAB’s over the last 12 months.

YMAB's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as ENSC (99) in the null industry. This means that YMAB’s stock grew similarly to ENSC’s over the last 12 months.

YMAB's Price Growth Rating (64) in the Pharmaceuticals Major industry is in the same range as ENSC (93) in the null industry. This means that YMAB’s stock grew similarly to ENSC’s over the last 12 months.

ENSC's P/E Growth Rating (68) in the null industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that ENSC’s stock grew similarly to YMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENSCYMAB
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
88%
MACD
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 6 days ago
81%
Declines
ODDS (%)
Bearish Trend 20 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
81%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ENSC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCGIX35.020.21
+0.60%
Goldman Sachs Large Cap Gr Insghts Instl
BGRIX91.980.39
+0.43%
Baron Growth Instl
MAIJX19.240.08
+0.42%
Morgan Stanley Inst Passport ovrs eq R6
GCVIX23.900.03
+0.13%
Goldman Sachs Large Cp Val Insghts Instl
CPAYX10.820.01
+0.09%
Integrity Dividend Summit C

ENSC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENSC has been loosely correlated with MLLCF. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ENSC jumps, then MLLCF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENSC
1D Price
Change %
ENSC100%
+0.90%
MLLCF - ENSC
37%
Loosely correlated
N/A
HNSBF - ENSC
33%
Loosely correlated
N/A
SYRE - ENSC
31%
Poorly correlated
-4.99%
NEUP - ENSC
31%
Poorly correlated
+2.94%
YMAB - ENSC
30%
Poorly correlated
-2.08%
More

YMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with ARWR. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
-2.08%
ARWR - YMAB
53%
Loosely correlated
N/A
OCUL - YMAB
51%
Loosely correlated
-2.54%
CRSP - YMAB
50%
Loosely correlated
N/A
FATE - YMAB
48%
Loosely correlated
-5.45%
IPSC - YMAB
47%
Loosely correlated
-5.74%
More